Article
[Molecular pathological diagnosis in cytopathology of non-small-cell lung cancer. Standardization of specimen processing].
Der Pathologe - 1 Jul 2013
Warth A, Bubendorf L, Gütz S, Morresi-Hauf A, Hummel M, Junker K, Lehmann U, Petersen I, Schnabel P A
Abstract excerpt
BACKGROUND: Personalized medicine is becoming standard for the treatment of non-small-cell lung cancer. For example, patients with activating EGFR mutations or EML4-ALK translocations largely benefit from targeted therapies with tyrosine kinase inhibitors with better response rates and progression-free survival compared to standard chemotherapy regimens. However, the application of the respective molecular...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.